Evidence map›Paper›PMID 42680753›Full record

ArticleCell death discovery2026

The insulin-like growth factor 2 mRNA-binding protein 2 affects tumor cell metabolism via mitochondrial transporter activity and lipid alterations.

Sandra Kendzia, Susanne Franke, Marcello Pirritano, Eva Grafahrend-Belau, Nikolai Köhler, Theresa Bauchspiess, Sören Franzenburg, Marcus Höring, Elia Raab, Linus Schmeier and 10 more

Abstract read
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Sandra Kendzia *Experimental Pharmacology for Natural Sciences, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Susanne Franke *Experimental Pharmacology for Natural Sciences, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Marcello PirritanoMolecular Cell Biology and Microbiology, University of Wuppertal, Wuppertal, Germany.ORCID http://orcid.org/0000-0001-5503-2614
Eva Grafahrend-BelauBiosynthesis of Active Substances, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Nikolai KöhlerLipiTUM, Chair of Experimental Bioinformatics, TUM School of Life Sciences, Technical University of Munich, Freising, Germany.
Theresa BauchspiessExperimental Pharmacology for Natural Sciences, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Sören FranzenburgCompetence Centre for Genomic Analysis, Kiel, Germany.
Marcus HöringInstitute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0002-3651-392X
Elia RaabExperimental Pharmacology for Natural Sciences, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.ORCID http://orcid.org/0009-0002-2152-2791
Linus SchmeierDepartment of Visceral, Vascular and Endocrine Surgery, University Medical Center Halle (Saale), Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Sinem SürmeliInstitute of Molecular Medicine, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Frank ErdmannExperimental Pharmacology for Natural Sciences, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Johannes KloseDepartment of Visceral, Vascular and Endocrine Surgery, University Medical Center Halle (Saale), Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Jörg KleeffDepartment of Visceral, Vascular and Endocrine Surgery, University Medical Center Halle (Saale), Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Michael BoettcherInstitute of Molecular Medicine, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Gerhard LiebischInstitute for Clinical Chemistry and Laboratory Medicine, University of Regensburg, Regensburg, Germany.
Josch K PaulingLipiTUM, Chair of Experimental Bioinformatics, TUM School of Life Sciences, Technical University of Munich, Freising, Germany.
Martin SimonMolecular Cell Biology and Microbiology, University of Wuppertal, Wuppertal, Germany.ORCID http://orcid.org/0000-0002-0962-7788
Björn H JunkerBiosynthesis of Active Substances, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Sonja M KesslerExperimental Pharmacology for Natural Sciences, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany. pharmakologie@pharmazie.uni-halle.de.ORCID http://orcid.org/0000-0002-8591-851X

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) project 407495230Deutsche Forschungsgemeinschaft (German Research Foundation) project 423957469
6 · The paper itself

Abstract

The insulin-like growth factor 2 mRNA-binding protein (IGF2BP) family is overexpressed in cancer and associated with poor prognosis. IGF2BP2 has been linked to single metabolic alterations by acting on its RNA targets. Here, we used a comprehensive approach to elucidate the effects of IGF2BP2 on primary and lipid metabolism.

Identifiers

PMID42680753
PMCPMC13534510

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.